CT radiomics-based long-term survival prediction for locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy using features from tumor and tumor organismal environment

Abstract

Background Definitive concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced non-small cell lung cancer (LANSCLC) patients, but the treatment response and survival outcomes varied among these patients. We aimed to identify pretreatment computed tomography-based radiomics features extracted from tumor and tumor organismal environment (TOE) for long-term survival prediction in these patients treated with CCRT. Methods A total of 298 eligible patients were randomly assigned into the training cohort and validation cohort with a ratio 2:1. An integrated feature selection and model training approach using support vector machine combined with genetic algorithm was performed to predict 3-year overall survival (OS). Patients were stratified into the high-risk and low-risk group based on the predicted survival status. Pulmonary function test and blood gas analysis indicators were associated with radiomic features. Dynamic changes of peripheral blood lymphocytes counts before and after CCRT had been documented. Results Nine features including 5 tumor-related features and 4 pulmonary features were selected in the predictive model. The areas under the receiver operating characteristic curve for the training and validation cohort were 0.965 and 0.869, and were reduced by 0.179 and 0.223 when all pulmonary features were excluded. Based on radiomics-derived stratification, the low-risk group yielded better 3-year OS (68.4% vs. 3.3%, p < 0.001) than the high-risk group. Patients in the low-risk group had better baseline FEV1/FVC% (96.3% vs. 85.9%, p = 0.046), less Grade ≥ 3 lymphopenia during CCRT (63.2% vs. 83.3%, p = 0.031), better recovery of lymphopenia from CCRT (71.4% vs. 27.8%, p < 0.001), lower incidence of Grade ≥ 2 radiation-induced pneumonitis (31.6% vs. 53.3%, p = 0.040), superior tumor remission (84.2% vs. 66.7%, p = 0.003). Conclusion Pretreatment radiomics features from tumor and TOE could boost the long-term survival forecast accuracy in LANSCLC patients, and the predictive results could be utilized as an effective indicator for survival risk stratification. Low-risk patients might benefit more from radical CCRT and further adjuvant immunotherapy. Trial registration: retrospectively registered.

Early recovery of leukocyte subsets is associated with progression-free survival in patients with inoperable stage III NSCLC after multimodal treatment: a prospective explorative study

“…Comparable to findings of previously published studies [10], [11], [12], [13], all patients in this study experienced moderate to severe lymphocytopenia during RT (A.2-RTend) with the nadir at the end of radiotherapy. Most of our patients recovered from lymphocytopenia within the following 3 (C.2) to 6 (C.3) mo.…”

Integrating Omics Data and AI for Cancer Diagnosis and Prognosis: A Systematic Review

“…However, these diverse datasets often comprise a substantial number of features. Some studies have noted overfitting in their models due to the utilization of a larger number of features relative to a smaller sample size [66,96]. This issue is commonly referred to as the 'n << P problem,' where 'n' represents the sample size and 'P' denotes the number of features [102].…”

Support Vector Machine Approaches for Tumor Classification and Survival Prediction in Cancer Patients: A Multi-Omics Data Analysis

“…The study utilized multi-omics information gotten from cancer patients, counting genomic, transcriptomic, proteomic, and metabolomic profiles. The information were collected from freely accessible databases and collaborative inquire about activities, guaranteeing a different representation of cancer sorts and clinical results [4]. Preprocessing steps included information normalization, include selection, and integration to guarantee consistency and compatibility over distinctive omics stages.…”